New Jersey is positioned to benefit from a surge in pharmaceutical industry investment as companies consider moving overseas research and manufacturing operations back to the United States. This shift could result in significant construction projects, job creation, and increased economic activity for states that successfully attract these businesses.
Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ), and William Mullen, President of the New Jersey Building and Construction Trades Council, commented on this development: “New Jersey faces an unprecedented opportunity over the next few months as America’s pharmaceutical industry looks to double down on American investment by relocating overseas R&D and manufacturing facilities to various locations around the United States and expanding some of our American-based facilities.”
They added: “These investments in America will mean tens (if not hundreds) of billions of dollars in construction projects, increased jobs and greater economic activity for whatever states are lucky enough – or smart enough – to attract these companies, their new facilities, and the jobs they will generate.”
The potential influx of pharmaceutical investments comes at a time when several U.S. states are competing to become destinations for these new or expanded operations. For New Jersey, which has a long history with the life sciences sector, this represents both an urgent challenge and a unique chance to strengthen its economy.
